Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
EMS
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Signed Consent;
Participants with diagnosis of open-angle glaucoma or hypertension ocular, who needs treatment with drugs association to control the intraocular pressure;
Participants who have 20/80 visual acuity or more, in both eyes;
You may not be if
Participants with any clinical significant disease that, after evaluation of the investigator, can´t participate in the study;
Participants with active eye disease, which in the investigator opinion may interfere in the results of this clinical trial;
Participants presenting previous diagnosis of non-operated cataract, high myopia, high astigmatism, pseudoexfoliation and corneal deformities;
Participants who had significant visual loss in the last year;
Treatment-naive participants for open-angle glaucoma or ocular hypertension;
Participants nonresponders to previous triple combination drug therapy, used in concomitance;
Participants with previous ocular or intraocular surgery within six months prior to enrollment in the clinical trial;
Participants with history of hypersensitivity to any formula compounds;
Participants presenting contraindications to use of beta-adrenergic antagonists;
Participants diagnosed with uncontrolled cardiovascular disease;
Participants with severe renal insufficiency or hyperchloremic acidosis;
Participants in therapy with monoamine oxidase inhibitors (MAOIs);
Participants who were in use of drugs that can interfere in the evaluation;
Pregnancy or risk of pregnancy and lactating patients;
Alcoholism or illicit drug abuse in the last two years;
Participation in clinical trial in the year prior to this study.
Clareo Health | BREMEN Eye Drops Versus Combigan for Open-angle Glaucoma or Intraocular Hypertension
